Nature biomedical engineering · 2024
Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yin Di, Zhong Yiye, Ling Sikai, Lu Sicong, Wang Xiaoyuan, Jiang Zhuofan, Wang Jie, Dai Yao, Tian Xiaolong, Huang Qijing, Wang Xingbo, Chen Junsong, Li Ziying, Li Yang, Xu Zhijue, Jiang Hewei, Wu Yuqing, Shi Yi, Wang Quanjun, Xu Jianjiang, Hong Wei, Xue Heng, Yang Hang, Zhang Yan, Da Lintai, Han Ze-Guang, Tao Sheng-Ce, Dong Ruijiao, Ying Tianlei, Hong Jiaxu, Cai Yujia
Аннотация
Messenger RNA vaccines lack specificity for dendritic cells (DCs)-the most effective cells at antigen presentation. Here we report the design and performance of a DC-targeting virus-like particle pseudotyped with an engineered Sindbis-virus glycoprotein that recognizes a surface protein on DCs, and packaging mRNA encoding for the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or for the glycoproteins B and D of herpes simplex virus 1. Injection of the DC-targeting SARS-CoV-2 mRNA vaccine in the footpad of mice led to substantially higher and durable antigen-specific immunoglobulin-G titres and cellular immune responses than untargeted virus-like particles and lipid-nanoparticle formulations. The vaccines also protected the mice from infection with SARS-CoV-2 or with herpes simplex virus 1. Virus-like particles with preferential uptake by DCs may facilitate the development of potent prophylactic and therapeutic vaccines.